Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: As the use of continuous glucose monitoring (CGM) has increased, time in range (TIR) and other core CGM metrics are now emerging as the core metrics for clinical targets and assessing diabetic complications, beyond HbA1c. This study investigated the association between the CGM-derived TIR, hyperglycemia, hypoglycemia metrics, and albuminuria. Methods: A total of 866 subjects with type 2 diabetes who underwent 3 or 6 days of CGM and had urinary albumin-to-creatinine ratio (ACR) measurements were retrospectively reviewed. CGM metrics were defined according to the most recent international consensus. Albuminuria was defined as one or more of the ACR measurements being >30 mg/g. Results: The overall prevalence of albuminuria was 36.6%. The prevalence of albuminuria was lower in subjects who achieved the target of TIR 70–180 mg/dL, time above range (TAR) >180 mg/dL, and TAR >250 mg/dL, as recommended by international consensus ( P < 0.001). Multiple logistic regression analysis revealed that the odds ratio of having albuminuria was 0.94 (95% confidence interval: 0.88–0.99, P for trend = 0.04) per 10% increase in TIR of 70–180 mg/dL, after adjusting for multiple factors, including glycemic variability. The results were similar for hyperglycemia metrics (TAR >250 mg/dL and TAR >180 mg/dL). Conclusions: TIR 70–180 mg/dL and hyperglycemia metrics are strongly associated with albuminuria in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 2×
“15 As the use of CGM is rapidly growing as an essential part of diabetes management in clinical practice, the need to investigate whether TIR and other CGM parameters are related to diabetes complications as HbA1c is increasing.”
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1×
“18,19 20–22 Nonetheless, previous studies on associations between albuminuria and CGM metrics, including TIR, are lacking.”
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793 · cited 4×
“32 Despite the short duration of CGM, this study used the longest CGM wear among studies showing correlation of TIR of target glucose and diabetes complications; previous studies used a 3-day TIR of target glucose and a seven-point SMBG.”
InfluentialZoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin
Bry, L., Chen, P. C., & Sacks, D. B. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.2.153 · Cited by 523
Lu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517 · cited 2×
“18,19 20–22 Nonetheless, previous studies on associations between albuminuria and CGM metrics, including TIR, are lacking.”
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479
Cappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
The relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
HbA1c levels are significantly lower in early and late pregnancy
Nielsen, L. R., Ekbom, P., Damm, P., Glümer, C., Frandsen, M. M., Jensen, D. M., & Mathiesen, E. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1200 · Cited by 331
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
The Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee, S. Y., & Kim, Y. S. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0105 · Cited by 274 · cited 2×
“The ORs for a 10% increase in TAR ( > 180 mg/dL) and TAR ( > 250 mg/dL) were 1.07 (95% CI: 1.01 - 1.19) and 1.10 (95% CI: 1.01–1.20), respectively, after adjustment for confounding factors, including CV.”
InfluentialSelf-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Continuous glucose monitoring sensors: past, present and future algorithmic challenges
Facchinetti, A. (2016) · Sensors · doi:10.3390/s16122093 · Cited by 176
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US
FORD, E. S., COWIE, C. C., LI, C., HANDELSMAN, Y., & BLOOMGARDEN, Z. T. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00100.x · Cited by 165
Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors
Klonoff, D. C., Parkes, J. L., Kovatchev, B. P., Kerr, D., Bevier, W. C., Brazg, R. L., Christiansen, M., Bailey, T. S., Nichols, J. H., & Kohn, M. A. (2018) · Diabetes Care · doi:10.2337/dc17-1960 · Cited by 144
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Metadata
- Authors
- Yoo, J. H., Choi, M. S., Ahn, J., Park, S. W., Kim, Y., Hur, K. Y., Jin, S.-M., Kim, G., & Kim, J. H.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-10-01
- Volume
- 22
- Issue
- 10
- Pages
- 768-776
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3010751516
- Cited by
- 98
- References
- 21
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.